TABLE 3.
DMT Administration and Monitoring Frequency and Health Care Provider Utilization for Models 1 and 2
| Model 1: PEG | Model 2: ALT | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| PEG | IM IFN beta-1a | SC IFN beta-1b | GA | FIN | NAT | DMF | ALT | IFN beta-1a 44 μg | |
| Drug administration | |||||||||
| Frequency | 26 | 52 | 183 | 365 | 365 | 13 | 730 | 8 | 312 |
| Monitoring | |||||||||
| Complete blood count24-30 | 3 | 2 | 3 | 1 | 2 | 1 | 3 | 25 | 6 |
| Liver function test24-29 | 3 | 2 | 3 | 1 | 1 | 1 | 0 | N/A | 6 |
| Magnetic resonance imaging29 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 9 | N/A |
| Electrocardiogram28 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 25 | N/A |
| Macular edema testing28 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 25 | N/A |
| Thyroid function test25 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 9 | N/A |
| Serum creatinine level | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 25 | N/A |
| Urineanalysis | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 25 | N/A |
| Skin test for melanoma | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3 | N/A |
| Health care provider visit | |||||||||
| Neurologist33 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 7 | 6 |
ALT = alemtuzumab; DMF = dimethyl fumarate; DMT = disease-modifying therapy; FIN = fingolimod; GA = glatiramer acetate; IFN = interferon; IM = intramuscular; N/A = not applicable; NAT = natalizumab; PEG = peginterferon beta-1a; SC = subcutaneous.